Biogen news

BGEN licensed its hepatitis B patent portfolio to SmithKline in 1988. SmithKline initiated the arbitration in 1993, pertaining to the rate of royalties the pharma company has paid BGEN since 1990. Because SmithKline continued paying royalties at the disputed rate during the arbitration, BGEN won't receive any payments as a result of the decision. ...